Olink

Olink®
Part of Thermo Fisher Scientific

A plasma protein-based risk score to predict hip fractures

Nature Aging, 2024

Austin T., Nethander M., Fink H., Törnqvist A., Jalal D., Buzkova P., Barzilay J., Carbone L., Gabrielsen M., Grahnemo L., Lu T., Hveem K., Jonasson C., Kizer J., Langhammer A., Mukamal K., Gerszten R., Psaty B., Robbins J., Sun Y., Skogholt A., Kanis J., Johansson H., Åsvold B., Valderrabano R., Zheng J., Richards J., Coward E., Ohlsson C.

Disease areaApplication areaSample typeProducts
Aging
Patient Stratification
Plasma
Olink Explore 3072/384

Olink Explore 3072/384

Abstract

As there are effective treatments to reduce hip fractures, identification of patients at high risk of hip fracture is important to inform efficient intervention strategies. To obtain a new tool for hip fracture prediction, we developed a protein-based risk score in the Cardiovascular Health Study using an aptamer-based proteomic platform. The proteomic risk score predicted incident hip fractures and improved hip fracture discrimination in two Trøndelag Health Study validation cohorts using the same aptamer-based platform. When transferred to an antibody-based proteomic platform in a UK Biobank validation cohort, the proteomic risk score was strongly associated with hip fractures (hazard ratio per s.d. increase, 1.64; 95% confidence interval 1.53–1.77). The proteomic risk score, but not available polygenic risk scores for fractures or bone mineral density, improved the C-index beyond the fracture risk assessment tool (FRAX), which integrates information from clinical risk factors (C-index, FRAX 0.735 versus FRAX + proteomic risk score 0.776). The developed proteomic risk score constitutes a new tool for stratifying patients according to hip fracture risk; however, its improvement in hip fracture discrimination is modest and its clinical utility beyond FRAX with information on femoral neck bone mineral density remains to be determined.

Read publication ↗